Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination and the following licensing of these epitope-specific CD8 T cells
CD: cluster of differentiation YF: yellow fever
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vaccine | Other | Yellow Fever Vaccine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Yellow Fever Vaccine | Drug | STAMARIL, powder and solvent for suspension for injection in pre-filled syringe. After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU. Powder and solvent for suspension for injection. Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 21(+/-3) days after vaccination with YF-17D | Measured by flow cytometry | 21(+/-3) days |
| Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 100 (+/- 40) days after vaccination with YF-17D | Measured by flow cytometry | 100 (+/- 40) days |
| Measure | Description | Time Frame |
|---|---|---|
| % of patients with novel yellow fever vaccine epitopes according to HLA-type defining optimal timepoint for T cell licensing | Measured by polymerase chain reaction | 21(+/-3) days |
| % of patients with novel yellow fever vaccine epitopes according to HLA-type defining optimal timepoint for T cell licensing |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jesper D Gunst, MD | Aarhus University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aarhus University Hospital | Aarhus | Denmark |
Not provided
| Label | URL |
|---|---|
| We have developed an immunotherapy technology in which potent CTL responses are generated in vivo by vaccination and redirected to eliminate target cells using a bispecific Redirector of Vaccine-induced Effector Responses (RoVER) | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D022341 | Yellow Fever Vaccine |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Measured by polymerase chain reaction |
| 100 (+/- 40) days |
| Proportion of target cells killed ex vivo from in vivo generated YF-specific CD8+ T cells | Measured by ex vivo killing assay | 21(+/-3) days |
| Proportion of target cells killed ex vivo from in vivo generated YF-specific CD8+ T cells | Measured by ex vivo killing assay | 100 (+/- 40) days |